Company ProfilePremium

Septodont Holding

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Septodont Holding - Company showcase

Year Founded & Workforce

1932

1,359 Employees

Septodont Holding logo

Septodont Holding Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Septodont Holding Overview

Listing status vs. input list: The input list classifies the company as a "Public company". This is incorrect. Septodont Holding is unlisted and privately held. Its capital is wholly owned by the Schiller family: the former CEO and current Chairman Olivier Schiller, his father Henri Schiller, and his five children.

Septodont is the world's largest maker of dental local anesthetics and a family-controlled specialist in pharmaceutical dentistry. Its core franchise is injectable anesthetic cartridges. The group produces about 500 million per year, which management characterizes as roughly 20 cartridges injected every second worldwide, and historically more than half of global production. Around that core, Septodont has built adjacent businesses: needles and injection devices, topical anesthetics, reversal agents, bioactive restorative and endodontic materials based on its proprietary Active BioSilicate Technology (Biodentine, BioRoot RCS, BioRoot Flow), and surgical biomaterials. A third leg is sterile-injectable contract manufacturing (CDMO) through Novocol Pharma in Canada, which counts Moderna as an anchor client. The group has grown from EUR 199M (2014) to EUR 443M (2024), an 8.3% CAGR, financed with bank debt rather than outside equity. The 2024 Inibsa acquisition lifts it toward ~EUR 560M. Management's stated ambition is EUR 1bn of revenue by the 2032 centenary.


What the company does

Septodont develops, manufactures and distributes dental pharmaceuticals and medical devices. The Chairman's January 2025 description of the group's production scope covers:

  • injectable anesthetics;

  • topical anesthetics (applied locally without injection);

  • needles;

  • anesthetic reversal agents ("neutraliseurs d'anesthésique");

  • safety injection devices and syringes.

Beyond pain control, the company is active in:

endodontics: root canal sealers and obturation materials, with files now added through a partnership;

restorative dentistry: dentine substitutes;

surgical dentistry: hemostatics, alveolar dressings and synthetic membranes;

infection control: and related consumables.

Company's own description

Company boilerplate (Indeed / corporate profile) describes Septodont as enhancing lives through innovative, safe and effective healthcare solutions. It positions the company at the forefront of pharmaceutical dentistry since the Schiller family founded it in 1932, as still family-owned, and as the world leader in dental pain management. No statutory annual report is published, so no annual-report description is available.

Business model and revenue model

Revenue streamNatureDisclosure status
Dental pain management (anesthetic cartridges, topicals, needles, syringes, reversal agents)Product sales of consumables, recurring and volume-drivenShare of revenue not publicly disclosed. The Chairman notes pain control is only ~5% of a dentist's consumables spend, which bounds the addressable market
Dental biomaterials, restorative, endodontic and surgical productsProduct sales of consumables—
CDMO (Novocol Pharma, Canada): aseptic fill-finish, labelling and packaging for third partiesContract manufacturing services, long-term supply agreements—
Licensing / subscriptionNo material licensing or subscription revenue identified—

The model is overwhelmingly a product model: high-volume regulated consumables sold mainly through dental distributors and dealers, plus subsidiaries in key markets. A smaller but strategic service model comes from CDMO. Distribution is via subsidiaries or distributor networks in about 110 countries (Chairman, 2025). Older corporate boilerplate cites 150+ countries; the difference likely reflects a change in definition, from countries supplied to countries with active presence. Septodont sells worldwide except North Korea, Venezuela and Iran (Chairman, 2025).

Value-chain position

Septodont is vertically integrated:

R&D and regulatory: R&D centres in France and Canada, and product registrations in many jurisdictions (e.g., a first-in-40-years anesthetic registration in Japan).

Active-ingredient formulation and sterile manufacturing: automated washing, filling and terminal sterilization of cartridges.

Component manufacturing: needles and injection devices at Mazamet/Aussillon, France.

Commercialization: country subsidiaries and dealers.

It outsources selectively. For example, Ultracain cartridges acquired from Sanofi continue to be manufactured by Sanofi in Frankfurt under contract (ZWP Online, March 2022).

Customer types and end-markets

  • General dental practitioners and specialists (endodontists, oral surgeons, pediatric dentists), reached mainly through dental distributors and DSOs. The group has a "Global VP, Corporate Accounts" role, implying a key-account and DSO channel.

  • Hospitals and dental schools.

  • Pharmaceutical and biotech companies, as CDMO clients (Moderna).

  • Government health systems and tenders (implied by registrations in many national markets).

Independent characterization

Septodont is a classic French "ETI" (mid-sized company) "hidden champion": a dominant share in a narrow, highly regulated, low-ticket but indispensable consumable, protected by regulatory barriers and sterile-manufacturing know-how. Its strategic challenge, stated openly by the Chairman, is growth beyond a niche it already leads. Management is addressing this along three lines:

  1. adjacency expansion within dentistry (biomaterials, endodontics);

  2. sterile-injectable CDMO;

  3. consolidation by acquisition (Sanofi dental brands, Inibsa).

The model is cash-generative, and the group has used leverage (capped at 3.5x EBITDA) rather than equity. That preserves family control but concentrates financial risk.

Strategy

Stated strategy (Chairman, Jan 2025)

Three growth avenues:

  1. Consolidate global leadership in dental pain management.

  2. Become a global dental player beyond anesthetics. Pain control is only ~5% of a dentist's EUR 100 consumables spend.

  3. Leverage sterile-injectable know-how in non-dental CDMO.

Strategic matrix (markets x products):

Long-term target: EUR 1bn revenue by 2032, the company's centenary.

Initiatives in the last 24 months

InitiativeDateDetail
Inibsa acquisitionOct 2024+~EUR 80M revenue, production capacity, footprint in 60+ countries
Balanced Pharma investmentDec 2024 / Jan 2025Next-gen anesthetics in standard cartridges
CEO successionMar–Jun 2025Khadr CEO; Schiller Chairman
Cost programme2,025Production costs -2% vs 2024; cost-focused finance executive hired
Saint-Maur modernizationAnnounced 2025~EUR 30M to sustain French output
Endodontic complete solution2,025BioRoot Flow combined with GenENDO files via partnership
AI deploymentOngoingSales prospect targeting, manufacturing root-cause analysis, pharmacovigilance reporting
CSR roadmap (four pillars)OngoingEnvironment, communities, human capital, values

Medium-term financial targets

  • FY2025 revenue ~EUR 560M.

  • EUR 1bn by 2032.

  • Leverage ≤3.5x EBITDA on acquisitions.

  • R&D 5–6% of revenue.

  • No margin targets publicly disclosed.

Products & Services

Pricing is not publicly disclosed for any product; products are sold through dealers at list prices that vary by country. Launch years are given only where verified.

Dental Pain Management

Product / brandDescription & capabilitiesTarget customerLaunch / notes
Septanest / Septocaine (articaine HCl 4% with epinephrine)Flagship injectable local anesthetic in cartridges. Articaine is used in >95% of local anesthesias in Germany (ZWP interview)GPs, all dental specialtiesUS approval (as Septocaine) obtained
Ultracain (articaine)Ex-Sanofi articaine brand, manufactured by Sanofi Frankfurt under contractGPs (strong in Germany/Europe)Acquired 2021–2022
Scandonest (mepivacaine)Vasoconstrictor-free and adrenaline variantsGPs, pediatric, cardiac-risk patientsLong-established
Cook-Waite brand anestheticsUS legacy anesthetic brand (lidocaine and others)US dentistsAcquired 2017
Lidostesim (lidocaine), Mepivalem (mepivacaine), Citanest (prilocaine)Brazilian anesthetic brands produced at DLA CatanduvaBrazil / LatAmAcquired 2016
Inibsa anesthetic rangeSpanish-made dental anesthetics; Inibsa had presence in 60+ countriesIberia, LatAm, exportAcquired Oct 2024
Topical anesthetic gels (incl. lidocaine gel)Pre-injection gingival anesthesiaGPsThe Chairman cited a profitable lidocaine gel and a failed adjacent non-dental gel venture
OraVerse (phentolamine mesylate)Reversal of soft-tissue anesthesiaGPs, pediatricAcquired from Novalar, Mar 2011
New buffered / pH-neutralized anesthetic technologyRemoves acidity before injection for faster onset and less stingUS dentistsIn development / roll-out (Chairman 2025); launch date n/d
Japan-registered anestheticFirst new dental anesthetic registered in Japan in ~40 yearsJapanRegistered; year-1 sales limited by mandatory 1-year patient follow-up
Septoject needlesDental needles; ~200M needles/year from a dedicated plantAll dentistsMazamet plant
Ultra Safety Plus / Ultra Safety Plus Twist XLSafety syringe system to reduce needlestick injuriesHospitals, schools, clinicsCurrent
DentapenElectronic (battery-powered) injection syringe for controlled-flow injectionGPs, pediatricLaunched 2020
ParojectIntraligamentary / pressure syringeGPsCurrent
DontisolonEx-Sanofi dental corticosteroid preparationGPsAcquired 2021–2022

Biomaterials, Restorative, Endodontic & Surgical

Product / brandDescriptionTargetNotes
BiodentineTricalcium-silicate bioactive dentine substitute (Active BioSilicate Technology, ABS). Allows vital teeth to be preserved in deep caries instead of devitalizationRestorative, endodontic, pediatric>500 PubMed publications by 2019
BioRoot RCSABS bioceramic root canal sealerEndodontists, GPsCurrent
BioRoot FlowBioceramic root canal sealer in flowable format; designed to make obturation effective even for non-specialistsGPs, endodontistsRecent launch (announced ~2024)
GenENDOEndodontic file system, offered with BioRoot Flow as a complete obturation solution via a partnership with an instrument makerGPs, endodontistsGerman launch Sept 2025
Endomethasone NRoot canal pasteGPs1950s heritage product
AlveogylAlveolar osteitis (dry socket) dressingOral surgery / GPs1950s heritage product
RacestyptineHemostatic / retraction solutionRestorative, prosthodontics1950s heritage product
HemogelatinHemostatic gelatin sponge for bleeding managementOral surgeryCurrent
Synthetic surgical membranes (Biomedical Tissues)Fully synthetic post-extraction membrane, an alternative to bovine collagenOral surgeons, implantologistsAcquired 2022
TDV restorative accessoriesRestorative auxiliaries manufactured in PomerodeBrazil / LatAmAcquired 2014
Taloja (India) materialsMaterials and other solutionsExport, IndiaIndia revenue < EUR 5M

Digital and services

OfferingDescription
Septodont Companion appScan a product box to get country-specific product information and contact Septodont
CDMO services (Novocol Pharma)Aseptic fill-finish into vials and syringes, labelling and packaging for sterile injectables and combination products; anchor client Moderna (mRNA respiratory vaccines)
Duoject device engineeringInjection-device design and engineering services

Financial Narrative

Group-level income statement (consolidated)

Source: Chairman Olivier Schiller, École de Paris / La Fabrique transcript (session 21 Jan 2025). Currency: EUR. Septodont publishes no audited consolidated accounts.

Notes on the revenue figures:

  • FY2024 growth is +8.3% YoY (443/409).

  • The 10-year revenue CAGR for 2014–2024 is 8.3%, from EUR 199M in 2014. In the Q&A the Chairman also cited ~8.5% average growth.

  • FY2025 is guidance, not an actual: EUR 560M including ~EUR 80M from Inibsa, which implies organic plus other growth of ~EUR 37M (~8%).

  • CFNews (2024) cited Septodont revenue of ~EUR 410M at the time of the Inibsa deal, consistent with FY2023.

  • Revelio/Indeed estimates ("USD 100–500M") are superseded by the management figures.

Standalone accounts of SEPTODONT SAS (French operating company, SIREN 552 139 677)

Source: Pappers (RCS filings). EUR. The FY2025 revenue and net income are confirmed by Pappers' director page; the year labels for earlier columns are inferred from Pappers' standard newest-first ordering and should be checked against the filed accounts.

Latest export revenue for Septodont SAS is EUR 181M, roughly 78% of FY2025 standalone revenue. This shows the French entity functions largely as an export manufacturing and supply hub to group subsidiaries.

Interpretation: The French SAS's thin and volatile statutory margins are typical of a manufacturing and supply entity selling to affiliates under transfer pricing. They should not be read as group profitability. The FY2024 operating loss coincides with the Inibsa acquisition year and a cost-inflation issue flagged by the advisory board. In response, management hired a "cost killer" finance executive and set a 2025 target of a 2% cut in production costs (Chairman, Jan 2025). The FY2025 rebound to a EUR 7.58M operating profit is consistent with that programme.

Standalone accounts of SEPTODONT HOLDING SAS

Source: Pappers. Holding revenue reflects management fees and royalties; net income is likely dominated by subsidiary dividends.

Balance sheet, cash flow and ratios (group)

Disclosed financial policies (qualitative, Chairman 2025):

Leverage cap: net debt not to exceed 3.5x EBITDA on major acquisitions. Growth is financed with bank debt; private equity and Bpifrance-style equity are deliberately avoided to preserve control.

Capex commitment: ~EUR 30M to modernize the Saint-Maur-des-Fossés plant to keep French output stable. All future volume growth is to be located outside France.

Philanthropy: 0.5% of revenue (~EUR 2M/yr), the maximum tax-deductible rate.

R&D: 5–6% of revenue annually.

Ratios (ROE, ROA, ROIC, current ratio, D/E, net debt/EBITDA actuals, interest coverage, asset turnover, cash conversion cycle): not publicly disclosed. The only inference available is that post-Inibsa leverage is, by policy, at or below 3.5x EBITDA.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business lineContentsKey entities

Dental: Pain Management

Injectable anesthetic cartridges (articaine, lidocaine, mepivacaine, prilocaine), topical anesthetics, needles, safety and electronic syringes, reversal agent

Septodont SAS (Saint-Maur), Mazamet/Aussillon plant, Novocol (Cambridge), DLA (Catanduva), Inibsa (Spain)

Dental: Biomaterials, Restorative, Endodontic & Surgical

Biodentine, BioRoot RCS / BioRoot Flow, endodontic pastes, hemostatics, alveolar dressings, synthetic membranes, restorative accessories

Septodont SAS, TDV (Pomerode), Taloja (India), Biomedical Tissues

CDMO (non-dental)

Aseptic fill-finish, labelling and packaging of sterile injectables (vials and syringes), incl. mRNA vaccines

Novocol Pharma (Cambridge, ON)

Revenue by Segment

MetricFY2023FY2024

Group revenue (EUR Mn)

409443

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityCountryRoleDisclosed data

Septodont Holding SAS (428 207 922)

France

Family holding / top company

Standalone FY2022: revenue EUR 30M, net income EUR 25.1M, cash EUR 9.4M (Pappers)

Septodont SAS (552 139 677)

France

Main French operating company, Saint-Maur

Standalone FY2025 revenue EUR 232M (see §6)

Société Française d'Instruments de Chirurgie (Aussillon)

France

Needles and injection devices plant (Mazamet area)

FY2025 revenue EUR 12.7M, net income EUR 1.55M (Pappers)

Biomedical Tissues SAS (525 280 038)

France

Synthetic membranes

FY2022 revenue EUR 0.124M, net loss EUR 0.198M; 3–5 employees (2023)

Novocol Pharmaceutical of Canada Inc. (Novocol Pharma)

Canada

Anesthetic manufacturing and CDMO

500 employees (2023)

Duoject Medical Systems

Canada

Injection device design

—

Septodont Inc. / Septodont North America

USA

Commercial

—

TDV / DLA Pharma

Brazil

Manufacturing and commercial

—

Septodont India (Taloja)

India

Materials manufacturing

India revenue < EUR 5M (Chairman 2025)

Laboratorios Inibsa (controlling stake)

Spain

Anesthetics and dental products; ~EUR 80M revenue contribution

Acteon holds a minority stake

Septodont GmbH

Germany

Commercial (DACH), Niederkassel

—

Medtech (minority)

China

Distributor

—

Income Statement

MetricFY2023FY2024FY2025

Group revenue (EUR Mn)

409443—

Group revenue guidance (EUR Mn)

——560

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Revenue (EUR Mn)

180203205232

Operating result (EUR Mn)

8.235.84-3.157.58

Net income (EUR Mn)

4.571.65-1.352.09

Operating margin (%)

4.62.9-1.53.3

Net margin (%)

2.50.8-0.70.9

Cash (EUR Mn)

———3.03

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement (FY2022)

MetricFY2022

Revenue (EUR Mn)

30

Net income (EUR Mn)

25.1

Cash (EUR Mn)

9.4

Margin Analysis (%)

MetricFY2023FY2024

R&D spend (% of revenue, stated range midpoint)

5.55.5

Geographic Revenue

RegionFY2023 share of revenue (%)FY2023 revenue (EUR Mn, derived from 409 x share)

Americas (mainly US and Canada)

50204.5

Europe, Middle East & Africa

40163.6

Asia-Pacific

1040.9

Region Overview

RegionFY2023

Americas share (%)

50

EMEA share (%)

40

APAC share (%)

10

Country Overview

CountryDisclosure

India

Revenue < EUR 5M; pricing strategy to be reset (lower prices and margin to gain volume)

Brazil

Local manufacturing required to be competitive because of high import tariffs (TDV, DLA)

Japan

New anesthetic registration; slow initial uptake

Germany

Articaine >95% of local anesthesia; Ultracain and Septanest franchises

Spain / Iberia

Strengthened by Inibsa (from Oct 2024)

US

Largest single market (implied). Only ~50 sales reps, supported by an AI-based prospect-targeting tool that raised visit success from 2% to 20%

Analyst Conclusions

Management guidance: ~EUR 560M FY2025 revenue (including Inibsa); EUR 1bn by 2032; 2% production-cost reduction in 2025; ~EUR 30M Saint-Maur capex.

Consensus: none (no analyst coverage).

Implied growth: reaching EUR 1bn by 2032 from EUR 560M in 2025 requires a ~8.6% CAGR. That is in line with the past decade's 8.3%, but likely needs further acquisitions.

Bull case

  1. Inibsa integration plus cost discipline lifts scale and margins. The FY2025 standalone rebound at Septodont SAS (EUR 7.58M operating profit vs a EUR 3.15M loss) suggests the cost programme is working.

  2. CDMO becomes a meaningful second growth engine on the back of the Moderna line, with injectables outgrowing other dosage forms.

  3. Pipeline (buffered anesthetic, Balanced Pharma) and ABS biomaterials expand the addressable market beyond the ~5% pain-control slice.

Bear case

  1. Leverage up to 3.5x EBITDA combined with integration risk could strain cash if dental volumes or vaccine demand soften.

  2. Emerging-market price competition (India) and tariffs erode the anesthetic franchise.

  3. CEO transition and family succession, combined with Europe's cost and regulatory burden, may slow execution. Note that all incremental growth is to be located outside France.

Key catalysts and monitorables (next 12 months)

  • FY2025 actual consolidated revenue versus the EUR 560M guide.

  • Inibsa synergy delivery.

  • Novocol utilization and any new CDMO clients.

  • Balanced Pharma regulatory progress.

  • US launch of the buffered anesthetic.

  • Progress on the Saint-Maur modernization.

  • Further bolt-on M&A.

  • First CSRD report.

  • Any leadership changes under the new CEO.

Analyst verdict

Septodont is a high-quality, family-controlled niche champion whose core franchise, dental local anesthesia, is structurally defensive. Cartridges are low-cost, indispensable, consumed procedure by procedure and protected by regulatory approvals and sterile-manufacturing expertise that are hard to replicate. The group's track record is strong. It more than doubled revenue in a decade at an 8.3% CAGR without diluting family ownership, and it executed a series of acquisitions that each served a clear purpose: tariff-driven localization in Brazil, device engineering at Duoject, articaine consolidation through Sanofi's Ultracain, and scale and geography through Inibsa.

The investment case now hinges on three transitions happening at once. First, a leadership handover to Karim Khadr, the first CEO outside the founding family. Second, digesting Inibsa, the largest acquisition in the group's history, while holding leverage within its self-imposed 3.5x EBITDA ceiling. Third, proving that diversification into biomaterials, endodontic systems and CDMO can make Septodont less dependent on a market slice that represents only ~5% of dentist consumables spend.

The limited transparency is the main analytical constraint. There are no consolidated margins, cash flows or debt figures, and the French operating entity's thin statutory profits (EUR 2.09M net on EUR 232M revenue in FY2025) reflect intra-group transfer pricing rather than group economics. Even so, the qualitative signals are constructive: decisive cost action in 2025, a profit rebound at the French entity, a well-supported CDMO anchor in Moderna, and a credible innovation pipeline.

On balance, Septodont looks positioned to sustain high-single-digit growth. The EUR 1bn 2032 target is ambitious but consistent with history, provided M&A continues and leverage is managed prudently. The principal risks to monitor are integration execution, emerging-market price erosion, vaccine-volume volatility at Novocol and European cost competitiveness. Overall view: a resilient, well-governed private compounder with moderate execution risk over the next two to three years.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground

Karim Khadr

Chief Executive Officer; président of Biomedical Tissues (since 22 Sep 2025); officer of Septodont Holding and Septodont SAS (Pappers)

Joined 28 Jul 2021 as President, Dental Division; CEO since 2 Jun 2025

Born July 1964 (Pappers).

Olivier Schiller

Chairman (non-executive président)

CFO, then président 2012–Jun 2025; Chairman since Jun 2025

Engineer, École Centrale de Lille; Arthur Andersen consultant; HEC MBA. Advisor to Banque de France; Conseiller du Commerce extérieur; NYU College of Dentistry strategic council; VP of METI; ETI Ambassador to French government 2020–2022. Turned 65 in 2025

Henri Schiller

Shareholder; formerly chairman of supervisory board

Led company from the 1960s

Father of Olivier Schiller

Atif Zia

Chief Operating Officer, Septodont; President, Novocol Pharma; Board member, Balanced Pharma

—

Operations / CDMO leader

David Benovy

Global VP, Corporate Accounts

—

Ex-Dentsply, Dental Services Group

Jérôme Haas

Director of Corporate Marketing (as last reported)

——

Axel Reimann

Managing Director, Septodont GmbH (as last reported)

——

Major Shareholders

HolderStake

Schiller family (Henri Schiller, Olivier Schiller, his five children)

100% of Septodont (per Chairman, Jan 2025)

Institutional holders

None (unlisted)

Inibsa minority

Acteon holds a non-controlling stake in Inibsa (subsidiary level only)

Competitive Landscape

Competitors by Segment

Business lineCompetitors

Dental anesthetics

Dentsply Sirona; Pierrel S.p.A. (Italy, listed on Euronext Milan, articaine CMO/brand); Inibsa (now controlled by Septodont); Novocol legacy rivals; Hospira/Pfizer (historical); regional generics makers (India, China, Brazil)

Endodontics / biomaterials

Dentsply Sirona; Envista (Kerr); Coltene; FKG Dentaire; Angelus (Brazil, MTA); Brasseler; Ultradent

Restorative / bioactive

Solventum (ex-3M Oral Care); GC Corporation; Ivoclar; Kulzer; VOCO; Ultradent

Surgical biomaterials

Geistlich; Straumann Group; Zimmer Biomet Dental (now ZimVie / Envista lines)

Dental equipment / injection devices

Acteon (also Inibsa partner); Milestone Scientific (The Wand)

CDMO sterile fill-finish

Vetter, Recipharm, Baxter BioPharma Solutions (Simtra), Catalent (Novo Holdings), Delpharm, PCI Pharma

Peer Comparison FY2024

MetricSeptodontDentsply SironaEnvistaActeon

Ownership

Private, family

Listed (NASDAQ: XRAY)

Listed (NYSE: NVST)

Private

Latest revenue

EUR 443M (FY2024)

~USD 3.8bn (FY2024; verify in 10-K)

~USD 2.5bn (FY2024; verify in 10-K)

~EUR 200M (CFNews, 2024)

Revenue growth

+8.3% (FY2024)

Negative (FY2024; verify)

Flat to slightly negative (FY2024; verify)

—

Margins

—

Per 10-K

Per 10-K

—

R&D intensity

5–6%

Per 10-K

Per 10-K

—

Recent Developments

Relevant items from late 2024 and early 2025 are included for context and marked "(context)".

Not identified in public sources for this period: * litigation, regulatory actions, layoffs, restructurings or guidance revisions.

Company Snapshot

$479.4M

Revenue

1,359

Employees

1932

Founded

Saint-Maur-des-Fossés, France

Headquarters

SWOT Analysis

Strengths

  • Global #1 in dental anesthesia, with ~500M cartridges per year and historically >50% of world production.
  • Consistent growth: revenue EUR 199M (2014) to EUR 443M (2024), an 8.3% CAGR.
  • Proprietary ABS platform; Biodentine supported by >500 publications.
  • Vertically integrated manufacturing across 7+ sites on 3 continents, including needles (~200M/yr).
  • Long-term family ownership with a professional 9-member advisory board created in 2015 and an international executive committee.
  • Articaine leadership strengthened by Ultracain (Sanofi, 2021–2022), with articaine accounting for >95% of German local anesthesia.

Weaknesses

  • High dependence on dental anesthesia, which addresses only ~5% of dentist consumables spend.
  • Weak position in India (< EUR 5M revenue) and an acknowledged market misread.
  • Cost creep flagged by the advisory board, leading to a 2% production-cost-cut target for 2025.
  • Thin statutory profitability at the French operating company (FY2024 operating loss of EUR 3.15M).
  • A past failed diversification into non-dental topical gels erased earlier gains.
  • Very limited financial transparency, which constrains access to capital markets and benchmarking.

Opportunities

  • Inibsa synergies and footprint (+~EUR 80M revenue; 60+ countries).
  • CDMO growth, with Moderna as anchor client and injectables as the fastest-growing dosage form.
  • Buffered anesthetic and Balanced Pharma pipeline (US launches targeted by 2027).
  • Endodontic system play (BioRoot Flow plus GenENDO).
  • Synthetic membranes leveraging the group's distribution network.
  • AI-enabled commercial productivity: visit success up from 2% to 20% in the US.

Threats

  • Low-cost generic anesthetic competition (the Indian gel precedent; emerging markets).
  • European industrial cost and regulatory burden (CSRD), as warned by the Chairman.
  • Moderna / mRNA respiratory vaccine demand volatility affecting Novocol utilization.
  • Leverage up to 3.5x EBITDA amid higher interest rates.
  • Succession and family-governance risk: the Chairman's children are not yet ready to lead.
  • Tariff and trade policy shifts (US, Brazil) affecting cross-border supply.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
29 Oct 2024 (context)Inibsa controlling stake finalizedLargest acquisition in group history (~EUR 80M revenue)
13 Nov 2024 (context)GA_P publicizes advisory role for Acteon alongside Septodont HoldingConfirms Septodont Holding as the acquiring entity
19 Dec 2024 (context)Strategic investment in Balanced PharmaPipeline optionality in anesthesia
21 Jan 2025 (context)Chairman's seminar disclosing FY2023/2024 revenue, EUR 560M 2025 outlook, EUR 1bn 2032 goalKey financial disclosure
28 Jan 2025 (context)Balanced Pharma corporate minority round logged; Atif Zia joins BPI boardGovernance link
25 Feb 2025 (context)North American production hiring event announced (17–18 Mar 2025)Capacity ramp in Canada
19 Mar 2025 (context)Khadr named next CEO; Schiller to become ChairmanLeadership transition
25–29 Mar 2025Exhibits at IDS 2025, Cologne (Hall 4.1, A-091)Anesthesia and biomaterials showcase
2 Jun 2025Karim Khadr becomes CEOFirst non-family CEO era
Sep 2025La Fabrique publishes the Chairman's transcriptPublic strategic and financial disclosure
Sep 2025GenENDO file system launch announced for GermanyEndodontics expansion
Sep 2025Septodont interview series launched in German trade pressMarketing push in DACH
22 Sep 2025Khadr appointed président of Biomedical TissuesSubsidiary governance alignment
FY2025 (filed 2026)Septodont SAS standalone revenue EUR 232M (+13% vs EUR 205M), net income EUR 2.09MReturn to profit at French entity
FY2025 (filed 2026)Aussillon needle plant revenue EUR 12.7M, net income EUR 1.55MComponent plant profitable
2026 (updated May 2026)Wikipedia and third-party profiles updated to reflect Khadr as CEOPublic record update
Jan–Dec 2026Ongoing participation in dental congresses (e.g., Expodental, IDEM Singapore)Routine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Group revenue rose from EUR 409 Mn in FY2023 to EUR 443 Mn in FY2024.
Septodont Holding — Revenue by Segment
Series (EUR Mn)FY2023FY2024
Group revenue409443

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. La Fabrique de l'industrie / École de Paris du management: "Septodont, dix ans après, la marche en avant continue" (session 21 Jan 2025; published Sep 2025) (la-fabrique.fr)
  2. La Fabrique: "Comment poursuivre sa croissance quand on est leader mondial ?" (2015) (la-fabrique.fr)
  3. Pappers: Septodont SAS · Karim Khadr director page
  4. GLEIF / Bloomberg LEI (lei.bloomberg.com)
  5. Topograph (RCS data) (topograph.co)
  6. Dental Product Shopper (19 Mar 2025 governance release) (dentalproductshopper.com)
  7. ZWP Online (CEO appointment; Sanofi portfolio completion; GenENDO)
  8. Dental Tribune (Khadr joins, 2021) (dental-tribune.com)
  9. DDA & Company / Dentons / GA_P (Inibsa, Oct–Nov 2024)
  10. CFNews: "Septodont et Acteon se renforcent en Espagne"
  11. Dimensions of Dental Hygiene / Dr. Bicuspid / CB Insights (Balanced Pharma)
  12. Moderna / BioSpace (4 May 2023); Life Sciences BC (line inauguration); Waterloo EDC (Novocol); Government of Ontario release
  13. DentistryIQ (OraVerse 2011); Endo Practice US (DLA 2016)
  14. Revelio Labs (employees); Indeed; World Economic Forum profile; Wikipedia (Septodont); SustainabilityReports.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.